Literature DB >> 33613759

Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data.

Lixia Wu1, Lina Zhu2, Kequn Xu2, Siyuan Zhou2, Yang Zhou2, Tiening Zhang3, Junjie Hang2,4, Benny Chung-Ying Zee4.   

Abstract

Background: There is limited consensus on whether metastatic patterns are correlated with prognosis and treatment efficacy in pancreatic cancer. A better understanding of clinical implication of the metastatic patterns is pivotal for therapeutic decision-making and drug development.
Methods: This study included 977 patients with metastatic pancreatic cancer (MPC) in three cohorts. The training cohort included 273 patients from clinical trial NCT00574275 and 367 patients from clinical trial NCT01124786. As the validation cohort, 337 patients from Changzhou No.2 People's Hospital and Shanghai General Hospital were enrolled. The correlations between different patterns of metastases and clinicopathological characteristics were investigated with the Pearson Chi-Square test. Kaplan-Meier analysis and log-rank test were applied to analyze the survival outcomes among groups with different metastatic patterns. The prognostic value of the number of metastatic sites and other variables was evaluated using the Cox regression model.
Results: MPC patients aged ≥65 years had a higher rate of lung metastasis and those with liver metastasis were prone to have a high level of carbohydrate antigen 19-9 (CA19-9). Additionally, patients with isolated lung metastasis had much better overall survival (OS) than those with isolated liver or peritoneum metastasis. Cox regression analyses showed that the number of metastatic sites was an independent prognostic factor for OS in patients with MPC. Furthermore, for patients with one-site or two-site metastasis, there was a significant difference in OS among patients receiving no chemotherapy, monotherapy and combination therapy. However, for patients with more than two metastatic sites, receiving combination therapy or monotherapy showed limited superiority in OS over receiving no chemotherapy.
Conclusion: MPC patients with isolated lung metastasis had better OS than those with isolated liver or peritoneum metastasis. Moreover, the number of metastatic sites showed prognostic and predictive value in patients with MPC. © The author(s).

Entities:  

Keywords:  lung metastasis; pancreatic cancer; predictive value; prognosis; site-specific metastases

Year:  2021        PMID: 33613759      PMCID: PMC7890328          DOI: 10.7150/jca.50317

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  4 in total

1.  Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis?

Authors:  Won-Gun Yun; Wooil Kwon; Youngmin Han; Hee Ju Sohn; Hyeong Seok Kim; Mirang Lee; Hongbeom Kim; Alexander S Thomas; Michael D Kluger; Jin-Young Jang
Journal:  Cancers (Basel)       Date:  2022-04-20       Impact factor: 6.575

2.  Research on Influencing Factors of Clinical Efficacy of Meniscus Resection Based on Logistic Regression Analysis.

Authors:  Xiaocheng Mao; Qingnan Hong; Ruijin You; Yizhe Lu; Feng Zhao
Journal:  Scanning       Date:  2022-05-18       Impact factor: 1.750

3.  Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database.

Authors:  Catherine Conti; Frédéric Pamoukdjian; Thomas Aparicio; Soraya Mebarki; Johanne Poisson; Gilles Manceau; Julien Taieb; Bastien Rance; Sandrine Katsahian; Anaïs Charles-Nelson; Elena Paillaud
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

4.  The survival impact of palliative radiotherapy on synchronous metastatic pancreatic ductal adenocarcinoma: metastatic site can serve for radiotherapy-decision.

Authors:  Biaoxiang Xu; Yuan Zhou; Qian Pei; Fengbo Tan; Lilan Zhao; Cenap Güngör; Dan Wang; Yuqiang Li; Wenxue Liu; Zhongyi Zhou
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.